Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kohn

Showing results (321-330 of 369) with videos related to

Pageof 37
Sort By:
Gynecologic Oncology|August 5, 2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatmentJung-Min Lee, Christina M Annunziata, John L Hays, et al.
Biotechniques|September 20, 2002
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assayT G Zogakis, N G Costouros, E A Kruger, et al.
Oncology Letters|September 14, 2019
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8<sup>+</sup> T cells compared with women with BRCA wild-type disease during the early disease courseJung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, et al.
Molecular Cancer Therapeutics|October 15, 2008
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell linesPhilip L Lorenzi, Jenny Llamas, Michele Gunsior, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interactionE C Kohn, E Reed, G A Sarosy, et al.
Cancer Biology & Therapy|December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut, Nehal J Lakhani, James L Gulley, et al.
Molecular & Cellular Proteomics : MCP|March 2, 2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohortNilofer Azad, Minshu Yu, Ben Davidson, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 16, 2010
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibLokesh Jain, Tristan M Sissung, Romano Danesi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 14, 2024
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy ParticipantsYingmiao Liu, Jiatong Li, Jing Lyu, et al.
Endocrine-Related Cancer|May 28, 2004
High-resolution serum proteomic features for ovarian cancer detectionT P Conrads, V A Fusaro, S Ross, et al.
Pageof 37

Showing results (321-330 of 369) with videos related to

Sort By:
Pageof 37
Gynecologic Oncology|August 5, 2020
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatmentJung-Min Lee, Christina M Annunziata, John L Hays, et al.
Biotechniques|September 20, 2002
Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assayT G Zogakis, N G Costouros, E A Kruger, et al.
Oncology Letters|September 14, 2019
Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8<sup>+</sup> T cells compared with women with BRCA wild-type disease during the early disease courseJung-Min Lee, Dana-Adriana Botesteanu, Yusuke Tomita, et al.
Molecular Cancer Therapeutics|October 15, 2008
Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell linesPhilip L Lorenzi, Jenny Llamas, Michele Gunsior, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interactionE C Kohn, E Reed, G A Sarosy, et al.
Cancer Biology & Therapy|December 17, 2005
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumorsWilliam L Dahut, Nehal J Lakhani, James L Gulley, et al.
Molecular & Cellular Proteomics : MCP|March 2, 2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohortNilofer Azad, Minshu Yu, Ben Davidson, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 16, 2010
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibLokesh Jain, Tristan M Sissung, Romano Danesi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 14, 2024
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy ParticipantsYingmiao Liu, Jiatong Li, Jing Lyu, et al.
Endocrine-Related Cancer|May 28, 2004
High-resolution serum proteomic features for ovarian cancer detectionT P Conrads, V A Fusaro, S Ross, et al.
Pageof 37